Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DCFPyL PET/CT in High Risk Prostate Cancer
NCT03976843Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2019
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of piflufolastat f 18 in prostate cancer (PCa), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 4 years. Started Dec 2019; status: active, not recruiting.
02
Drugs
piflufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03976843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976843.